United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of Company Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction on Friday, September 25th. The shares were sold at an average price of $476.17, for a total value of $4,523,615.00. Following the completion of the transaction, the chief executive officer directly owned 324,443 shares in the company, valued at $154,490,023.31. This trade represents a 2.84% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

United Therapeutics Stock Up 2.1%

UTHR traded up $10.09 on Monday, reaching $485.54. The company’s stock had a trading volume of 602,466 shares, compared to its average volume of 517,539. The company has a market capitalization of $20.82 billion, a price-to-earnings ratio of 17.37, a P/E/G ratio of 2.38 and a beta of 0.56. United Therapeutics Corporation has a fifty-two week low of $409.07 and a fifty-two week high of $609.35. The stock has a 50 day moving average of $510.86 and a two-hundred day moving average of $540.13.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The business had revenue of $783.30 million during the quarter, compared to analysts’ expectations of $804.65 million. During the same quarter in the prior year, the business posted $6.41 EPS. The company’s revenue for the quarter was down 1.9% on a year-over-year basis. As a group, analysts anticipate that United Therapeutics Corporation will post 26.21 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

UTHR has been the subject of a number of recent research reports. Morgan Stanley set a $515.00 price target on shares of United Therapeutics in a research note on Thursday, August 6th. The Goldman Sachs Group started coverage on United Therapeutics in a research note on Thursday. They issued a “sell” rating and a $321.00 target price on the stock. Bank of America cut their price objective on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a research report on Friday, July 10th. Weiss Ratings cut United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday, August 27th. Finally, Royal Bank Of Canada decreased their price target on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating on the stock in a research note on Thursday, August 6th. Eleven investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, United Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $621.00.

Institutional Investors Weigh In On United Therapeutics

A number of large investors have recently bought and sold shares of the stock. Callan Family Office LLC acquired a new position in shares of United Therapeutics in the second quarter valued at approximately $1,217,000. Nicholas Investment Partners LP grew its holdings in United Therapeutics by 478.5% in the 4th quarter. Nicholas Investment Partners LP now owns 4,553 shares of the biotechnology company’s stock valued at $2,218,000 after buying an additional 3,766 shares during the period. Canada Pension Plan Investment Board purchased a new position in shares of United Therapeutics during the 2nd quarter worth about $3,359,000. Havemeyer Place LP acquired a new stake in shares of United Therapeutics in the fourth quarter worth approximately $2,189,000. Finally, Seven Fleet Capital Management LP acquired a new position in United Therapeutics during the fourth quarter worth approximately $633,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening conditions, with a primary emphasis on pulmonary arterial hypertension (PAH). The company’s products are designed to improve pulmonary blood flow and reduce the effects of this progressive disease.

United Therapeutics’ PAH portfolio includes Remodulin (treprostinil) injection, Orenitram (treprostinil) extended-release tablets, and Tyvaso (treprostinil), which is available as an inhalation solution and as the Tyvaso DPI dry-powder inhaler.